Protective effect of pentoxifylline on amikacin-induced ototoxicity in rats.
OBJECTIVE
This experimental study was performed to investigate the possible protective effect of pentoxifylline (PTX) on amikacin-induced ototoxicity in rats.


METHODS
In this study, 21 healthy female rats were randomly assigned to 1 of 3 groups: the amikacin group (n = 8), the amikacin + PTX group (n = 8), and the control group (n = 5). The amikacin group received amikacin (200 mg·kg(-1)·day(-1)) intramuscularly once daily for 14 days. The amikacin + PTX group received intramuscular injections of amikacin (200 mg·kg(-1)·day(-1)) once daily for 14 days and PTX (25 mg·kg(-1)·day(-1)) once daily via gastric gavage for 14 days. The control group received saline solution (1 mL·day(-1) intraperitoneal injections) once daily for 14 days. The hearing levels of the rats were evaluated using distortion product otoacoustic emissions before and after treatment.


RESULTS
The distortion product otoacoustic emissions' amplitude levels (decibel, sound pressure levels) measured before and after treatment at frequencies of 4000, 6000, and 8000 Hz revealed that values of the amikacin group dropped significantly at the end of treatment (P < .01). In contrast, the amikacin + PTX and the control groups showed no significant difference at the end of the treatment compared with the initial measurements (P > .05).


CONCLUSIONS
The results showed that PTX has protective effects on hearing functions in amikacin-induced ototoxicity in rats.
Okmeydani Training and Research Hospital Şişli, İstanbul, Turkey.
Güler
G
Berkiten
Ziya
Z
Salturk
Ilhan
I
Topaloğlu
Hilmi
H
Uğraş
D000583:Amikacin / Q000633:toxicity*; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects*; D010431:Pentoxifylline / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar
D010726:Phosphodiesterase Inhibitors; D000583:Amikacin; D010431:Pentoxifylline